Stock comparison
ResMed
Telix Pharmaceuticals Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
TLX
Telix Pharmaceuticals Limited
Market cap
$3.21B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TLX | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 31F | RMD |
| Benjamin Graham | 75B | 49D | RMD |
| Philip Fisher | 75B | 50C | RMD |
| Peter Lynch | 58C | 29F | RMD |
| Joel Greenblatt | 47D | 0F | RMD |
| Charlie Munger | 69B | 44D | RMD |
| Terry Smith | 73B | 38D | RMD |
Side-by-side metrics
| Metric | RMD | TLX |
|---|---|---|
| Market cap | $30.18B | $3.21B |
| P/E (TTM) | 19.6x | - |
| EV/EBIT | 17.1x | 211.6x |
| ROIC (TTM) | 19.63% | 1.77% |
| Gross margin | 61.69% | 50.76% |
| Net margin | 27.44% | -0.89% |
| Revenue CAGR 5y | 12.64% | 2.55% |
| EPS CAGR 5y | 30.73% | - |
| Debt / Equity | 0.1x | 1.3x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Net margin27.44%vs -0.89%+103%
- Dividend yield1.14%vs 0.0%+100%
- EV/EBIT17.1xvs 211.6x+92%
- ROIC (TTM)19.63%vs 1.77%+91%
TLX leads on
- P/E (TTM)-vs 19.6x+104%
- Revenue CAGR 5y2.55%vs 12.64%+95%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.